India, June 27 -- Innovent Biologics, Inc. (IVBXF.OB) announced Friday that China's National Medical Products Administration or NMPA has approved mazdutide for chronic weight management in Chinese adults with overweight or obesity.
Mmazdutide is a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist.
The biopharmaceutical company focused on oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases said the approval of mazdutide was mainly based on data from GLORY-1, a Phase 3 pivotal clinical study conducted in Chinese adults with overweight or obesity.
In the trial, the primary endpoint and all key secondary endpoints of the study were successfully achieved in 2024.
The ...